Literature DB >> 1783442

Interpretive criteria of antimicrobial disk susceptibility tests with flomoxef.

H Grimm1.   

Abstract

320 recently isolated pathogens, 20 strains from each of 16 species, were investigated using Mueller-Hinton agar and DIN as well as NCCLS standards. The geometric mean of the agar dilution MICs of flomoxef were 0.44 mg/l for Staphylococcus aureus, 0.05 mg/l (Klebsiella oxytoca) to 12.6 mg/l (Enterobacter spp.) for enterobacteriaceae, 33.1 mg/l for Acinetobacter anitratus, 64 mg/l for Enterococcus faecalis, and more than 256 mg/l for Pseudomonas aeruginosa. For disk susceptibility testing of flomoxef a 30 micrograms disk loading and the following interpretation of inhibition zones using the DIN method were recommended: resistant-up to 22 mm (corresponding to MICs of 8 mg/l or more), moderately susceptible-23 to 29 mm (corresponding to MICs from 1 to 4 mg/l), and susceptible-30 mm or more (corresponding to MICs of 0.5 mg/l or less). The respective values for the NCCLS method using the American high MIC breakpoints are: resistant--up to 14 mm (corresponding to MICs of 32 mg/l or more), moderately susceptible--15 to 17 mm (corresponding to MICs of 16 mg/l), and susceptible--18 mm or more (corresponding to MICs of 8 mg/l or less).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1783442     DOI: 10.1007/bf01645537

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  2 in total

1.  Cefotiam susceptibility testing criteria.

Authors:  P C Fuchs; A L Barry; R N Jones; C Thornsberry
Journal:  J Clin Microbiol       Date:  1985-12       Impact factor: 5.948

2.  In vitro activity and beta-lactamase stability of a new difluoro oxacephem, 6315-S.

Authors:  H C Neu; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

  2 in total
  5 in total

1.  Clinical epidemiology and molecular analysis of extended-spectrum-β-lactamase-producing Escherichia coli in Nepal: characteristics of sequence types 131 and 648.

Authors:  Jatan Bahadur Sherchan; Kayoko Hayakawa; Tohru Miyoshi-Akiyama; Norio Ohmagari; Teruo Kirikae; Maki Nagamatsu; Masayoshi Tojo; Hiroshi Ohara; Jeevan B Sherchand; Sarmila Tandukar
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

2.  Spread of ISCR1 elements containing blaDHA-₁ and multiple antimicrobial resistance genes leading to increase of flomoxef resistance in extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae.

Authors:  Chen-Hsiang Lee; Jien-Wei Liu; Chia-Chin Li; Chun-Chih Chien; Ya-Fen Tang; Lin-Hui Su
Journal:  Antimicrob Agents Chemother       Date:  2011-07-11       Impact factor: 5.191

3.  Microbiologic and clinical implications of bacteremia due to extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae with or without plasmid-mediated AmpC beta-lactamase DHA-1.

Authors:  Chen-Hsiang Lee; Lin-Hui Su; Chia-Chin Li; Chun-Chih Chien; Ya-Fen Tang; Jien-Wei Liu
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

4.  Clinical benefit of ertapenem compared to flomoxef for the treatment of cefotaxime-resistant Enterobacteriaceae bacteremia.

Authors:  Chen-Hsiang Lee; I-Ling Chen; Chia-Chin Li; Chun-Chih Chien
Journal:  Infect Drug Resist       Date:  2018-02-23       Impact factor: 4.003

5.  Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing Klebsiella pneumoniae in patients on maintenance hemodialysis.

Authors:  Chih-Chao Yang; Shau-Hsuan Li; Feng-Rong Chuang; Chih-Hung Chen; Chih-Hsiung Lee; Jin-Bor Chen; Chien-Hsing Wu; Chien-Te Lee
Journal:  BMC Infect Dis       Date:  2012-09-05       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.